electroCore, Inc.
NASDAQ:ECOR
electroCore, Inc.
Other Current Liabilities
electroCore, Inc.
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
electroCore, Inc.
NASDAQ:ECOR
|
Other Current Liabilities
$460k
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Other Current Liabilities
$6.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
476%
|
CAGR 10-Years
82%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Current Liabilities
$1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Current Liabilities
$859m
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
6%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Current Liabilities
$1.6B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Current Liabilities
$522.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
electroCore, Inc.
Glance View
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
See Also
What is electroCore, Inc.'s Other Current Liabilities?
Other Current Liabilities
460k
USD
Based on the financial report for Dec 31, 2024, electroCore, Inc.'s Other Current Liabilities amounts to 460k USD.
What is electroCore, Inc.'s Other Current Liabilities growth rate?
Other Current Liabilities CAGR 3Y
15%
Over the last year, the Other Current Liabilities growth was -11%. The average annual Other Current Liabilities growth rates for electroCore, Inc. have been 15% over the past three years .
You don't have any saved screeners yet